Results demonstrated 1 of 21 patients with EGFR+ tumors achieved PFS at 4-months (vs 3 of 15 among EGFR- tumors), leaving authors to conclude that there was no significant activity among patients with EGFR+ osteosarcoma [46]. Here, EGFR is linked to osteosarcoma.